The absolute monocyte and lymphocyte prognostic score predicts survival and identifies high-risk patients in diffuse large-B-cell lymphoma
Despite the use of modern immunochemotherapy regimens, almost 50% of patients with diffuse large-B-cell lymphoma will relapse. Current prognostic models, including the International Prognostic Index, incorporate patient and tumor characteristics. In contrast, recent observations show that variables...
Gespeichert in:
| Veröffentlicht in: | Leukemia 2011-09, Vol.25 (9), p.1502-1509 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1509 |
|---|---|
| container_issue | 9 |
| container_start_page | 1502 |
| container_title | Leukemia |
| container_volume | 25 |
| creator | Wilcox, R A Ristow, K Habermann, T M Inwards, D J Micallef, I N M Johnston, P B Colgan, J P Nowakowski, G S Ansell, S M Witzig, T E Markovic, S N Porrata, L |
| description | Despite the use of modern immunochemotherapy regimens, almost 50% of patients with diffuse large-B-cell lymphoma will relapse. Current prognostic models, including the International Prognostic Index, incorporate patient and tumor characteristics. In contrast, recent observations show that variables related to host adaptive immunity and the tumor microenvironment are significant prognostic variables in non-Hodgkin lymphoma. Therefore, we retrospectively examined the absolute monocyte and lymphocyte counts as prognostic variables in a cohort of 366 diffuse large-B-cell lymphoma patients who were treated between 1993 and 2007 and followed at a single institution. The absolute monocyte and lymphocyte counts in univariate analysis predicted progression-free and overall survival when analyzed as continuous and dichotomized variables. On multivariate analysis performed with factors included in the IPI, the absolute monocyte and lymphocyte counts remained independent predictors of progression-free and overall survival. Therefore, the absolute monocyte and lymphocyte counts were combined to generate a prognostic score that identified patients with an especially poor overall survival. This prognostic score was independent of the IPI and added to its ability to identify high-risk patients. |
| doi_str_mv | 10.1038/leu.2011.112 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_968174121</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A268310575</galeid><sourcerecordid>A268310575</sourcerecordid><originalsourceid>FETCH-LOGICAL-c542t-8542eceb741e67022c4b7998b8602bfc5bfefb4682d7fa5495710e9d33f46ec83</originalsourceid><addsrcrecordid>eNqF0k2P1CAYB_DGaNzZ1Ztn02hWL3YEChSO68a3ZBMv67mh9GHKSmGEdpP5Cn5q6c7oqNF46Qv8ysND_0XxBKM1RrV47WBeE4TxGmNyr1hh2vCKMYbvFyskRFNxSehJcZrSDULLJH9YnBDMEZesWRXfrgcoVZeCmycox-CD3uUH5fvS7cbtsH_dxrDxIU1Wl0mHuAxAb_WUyjTHW3ur3N0Xtgc_WWMhlYPdDFW06Uu5VZPNw6m0vuytMXOC0qm4gepNpcG5Q51RPSoeGOUSPD7cz4rP795eX36orj69_3h5cVVpRslUiXwFDV1DMfAGEaJp10gpOsER6YxmnQHTUS5I3xjFaG4TI5B9XRvKQYv6rHi5Xzd39XWGNLWjTctOlIcwp1ZygfPiBP9XCiGQRJyhLJ_9IW_CHH1uY0FE1qKhGT3_FyKcsoZITsVRbZSD1noTpqj0Uri9IFzUGLGGZfXiFzWActNw9xNt8Ol3-GoPdQwpRTDtNtpRxV2LUbsEqM0BapcAtTlAmT897HHuRuh_4h-JyeD8AFTSypmovLbp6Gg-cSmXs6v2LuUpv4F4bPavhb8DfGTcDg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2645729648</pqid></control><display><type>article</type><title>The absolute monocyte and lymphocyte prognostic score predicts survival and identifies high-risk patients in diffuse large-B-cell lymphoma</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><source>Nature</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Wilcox, R A ; Ristow, K ; Habermann, T M ; Inwards, D J ; Micallef, I N M ; Johnston, P B ; Colgan, J P ; Nowakowski, G S ; Ansell, S M ; Witzig, T E ; Markovic, S N ; Porrata, L</creator><creatorcontrib>Wilcox, R A ; Ristow, K ; Habermann, T M ; Inwards, D J ; Micallef, I N M ; Johnston, P B ; Colgan, J P ; Nowakowski, G S ; Ansell, S M ; Witzig, T E ; Markovic, S N ; Porrata, L</creatorcontrib><description>Despite the use of modern immunochemotherapy regimens, almost 50% of patients with diffuse large-B-cell lymphoma will relapse. Current prognostic models, including the International Prognostic Index, incorporate patient and tumor characteristics. In contrast, recent observations show that variables related to host adaptive immunity and the tumor microenvironment are significant prognostic variables in non-Hodgkin lymphoma. Therefore, we retrospectively examined the absolute monocyte and lymphocyte counts as prognostic variables in a cohort of 366 diffuse large-B-cell lymphoma patients who were treated between 1993 and 2007 and followed at a single institution. The absolute monocyte and lymphocyte counts in univariate analysis predicted progression-free and overall survival when analyzed as continuous and dichotomized variables. On multivariate analysis performed with factors included in the IPI, the absolute monocyte and lymphocyte counts remained independent predictors of progression-free and overall survival. Therefore, the absolute monocyte and lymphocyte counts were combined to generate a prognostic score that identified patients with an especially poor overall survival. This prognostic score was independent of the IPI and added to its ability to identify high-risk patients.</description><identifier>ISSN: 0887-6924</identifier><identifier>EISSN: 1476-5551</identifier><identifier>DOI: 10.1038/leu.2011.112</identifier><identifier>PMID: 21606957</identifier><identifier>CODEN: LEUKED</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>692/53/2422 ; 692/699/67/1990/291/1621/1915 ; Adaptive immunity ; Adult ; Aged ; Aged, 80 and over ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; B-cell lymphoma ; Biological and medical sciences ; Cancer Research ; Continuity (mathematics) ; Critical Care Medicine ; Development and progression ; Female ; Hematologic and hematopoietic diseases ; Hematology ; Humans ; Intensive ; Internal Medicine ; Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis ; Lymphocytes ; Lymphocytes - pathology ; Lymphocytes B ; Lymphoma ; Lymphoma, Large B-Cell, Diffuse - diagnosis ; Lymphoma, Large B-Cell, Diffuse - drug therapy ; Lymphoma, Large B-Cell, Diffuse - mortality ; Male ; Medical prognosis ; Medical sciences ; Medicine ; Medicine & Public Health ; Middle Aged ; Monocytes ; Monocytes - pathology ; Multivariate analysis ; Neoplasm Staging ; Non-Hodgkin's lymphoma ; Non-Hodgkin's lymphomas ; Oncology ; original-article ; Physiological aspects ; Prognosis ; Retrospective Studies ; Risk Factors ; Risk groups ; Survival ; Survival Rate ; Tumor microenvironment ; Tumors ; Young Adult</subject><ispartof>Leukemia, 2011-09, Vol.25 (9), p.1502-1509</ispartof><rights>Macmillan Publishers Limited 2011</rights><rights>2015 INIST-CNRS</rights><rights>COPYRIGHT 2011 Nature Publishing Group</rights><rights>Macmillan Publishers Limited 2011.</rights><rights>Copyright Nature Publishing Group Sep 2011</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c542t-8542eceb741e67022c4b7998b8602bfc5bfefb4682d7fa5495710e9d33f46ec83</citedby><cites>FETCH-LOGICAL-c542t-8542eceb741e67022c4b7998b8602bfc5bfefb4682d7fa5495710e9d33f46ec83</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1038/leu.2011.112$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1038/leu.2011.112$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=24549991$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21606957$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Wilcox, R A</creatorcontrib><creatorcontrib>Ristow, K</creatorcontrib><creatorcontrib>Habermann, T M</creatorcontrib><creatorcontrib>Inwards, D J</creatorcontrib><creatorcontrib>Micallef, I N M</creatorcontrib><creatorcontrib>Johnston, P B</creatorcontrib><creatorcontrib>Colgan, J P</creatorcontrib><creatorcontrib>Nowakowski, G S</creatorcontrib><creatorcontrib>Ansell, S M</creatorcontrib><creatorcontrib>Witzig, T E</creatorcontrib><creatorcontrib>Markovic, S N</creatorcontrib><creatorcontrib>Porrata, L</creatorcontrib><title>The absolute monocyte and lymphocyte prognostic score predicts survival and identifies high-risk patients in diffuse large-B-cell lymphoma</title><title>Leukemia</title><addtitle>Leukemia</addtitle><addtitle>Leukemia</addtitle><description>Despite the use of modern immunochemotherapy regimens, almost 50% of patients with diffuse large-B-cell lymphoma will relapse. Current prognostic models, including the International Prognostic Index, incorporate patient and tumor characteristics. In contrast, recent observations show that variables related to host adaptive immunity and the tumor microenvironment are significant prognostic variables in non-Hodgkin lymphoma. Therefore, we retrospectively examined the absolute monocyte and lymphocyte counts as prognostic variables in a cohort of 366 diffuse large-B-cell lymphoma patients who were treated between 1993 and 2007 and followed at a single institution. The absolute monocyte and lymphocyte counts in univariate analysis predicted progression-free and overall survival when analyzed as continuous and dichotomized variables. On multivariate analysis performed with factors included in the IPI, the absolute monocyte and lymphocyte counts remained independent predictors of progression-free and overall survival. Therefore, the absolute monocyte and lymphocyte counts were combined to generate a prognostic score that identified patients with an especially poor overall survival. This prognostic score was independent of the IPI and added to its ability to identify high-risk patients.</description><subject>692/53/2422</subject><subject>692/699/67/1990/291/1621/1915</subject><subject>Adaptive immunity</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>B-cell lymphoma</subject><subject>Biological and medical sciences</subject><subject>Cancer Research</subject><subject>Continuity (mathematics)</subject><subject>Critical Care Medicine</subject><subject>Development and progression</subject><subject>Female</subject><subject>Hematologic and hematopoietic diseases</subject><subject>Hematology</subject><subject>Humans</subject><subject>Intensive</subject><subject>Internal Medicine</subject><subject>Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis</subject><subject>Lymphocytes</subject><subject>Lymphocytes - pathology</subject><subject>Lymphocytes B</subject><subject>Lymphoma</subject><subject>Lymphoma, Large B-Cell, Diffuse - diagnosis</subject><subject>Lymphoma, Large B-Cell, Diffuse - drug therapy</subject><subject>Lymphoma, Large B-Cell, Diffuse - mortality</subject><subject>Male</subject><subject>Medical prognosis</subject><subject>Medical sciences</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>Monocytes</subject><subject>Monocytes - pathology</subject><subject>Multivariate analysis</subject><subject>Neoplasm Staging</subject><subject>Non-Hodgkin's lymphoma</subject><subject>Non-Hodgkin's lymphomas</subject><subject>Oncology</subject><subject>original-article</subject><subject>Physiological aspects</subject><subject>Prognosis</subject><subject>Retrospective Studies</subject><subject>Risk Factors</subject><subject>Risk groups</subject><subject>Survival</subject><subject>Survival Rate</subject><subject>Tumor microenvironment</subject><subject>Tumors</subject><subject>Young Adult</subject><issn>0887-6924</issn><issn>1476-5551</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNqF0k2P1CAYB_DGaNzZ1Ztn02hWL3YEChSO68a3ZBMv67mh9GHKSmGEdpP5Cn5q6c7oqNF46Qv8ysND_0XxBKM1RrV47WBeE4TxGmNyr1hh2vCKMYbvFyskRFNxSehJcZrSDULLJH9YnBDMEZesWRXfrgcoVZeCmycox-CD3uUH5fvS7cbtsH_dxrDxIU1Wl0mHuAxAb_WUyjTHW3ur3N0Xtgc_WWMhlYPdDFW06Uu5VZPNw6m0vuytMXOC0qm4gepNpcG5Q51RPSoeGOUSPD7cz4rP795eX36orj69_3h5cVVpRslUiXwFDV1DMfAGEaJp10gpOsER6YxmnQHTUS5I3xjFaG4TI5B9XRvKQYv6rHi5Xzd39XWGNLWjTctOlIcwp1ZygfPiBP9XCiGQRJyhLJ_9IW_CHH1uY0FE1qKhGT3_FyKcsoZITsVRbZSD1noTpqj0Uri9IFzUGLGGZfXiFzWActNw9xNt8Ol3-GoPdQwpRTDtNtpRxV2LUbsEqM0BapcAtTlAmT897HHuRuh_4h-JyeD8AFTSypmovLbp6Gg-cSmXs6v2LuUpv4F4bPavhb8DfGTcDg</recordid><startdate>20110901</startdate><enddate>20110901</enddate><creator>Wilcox, R A</creator><creator>Ristow, K</creator><creator>Habermann, T M</creator><creator>Inwards, D J</creator><creator>Micallef, I N M</creator><creator>Johnston, P B</creator><creator>Colgan, J P</creator><creator>Nowakowski, G S</creator><creator>Ansell, S M</creator><creator>Witzig, T E</creator><creator>Markovic, S N</creator><creator>Porrata, L</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7RV</scope><scope>7T5</scope><scope>7T7</scope><scope>7TM</scope><scope>7TO</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>NAPCQ</scope><scope>P64</scope><scope>PHGZM</scope><scope>PHGZT</scope><scope>PJZUB</scope><scope>PKEHL</scope><scope>PPXIY</scope><scope>PQEST</scope><scope>PQGLB</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20110901</creationdate><title>The absolute monocyte and lymphocyte prognostic score predicts survival and identifies high-risk patients in diffuse large-B-cell lymphoma</title><author>Wilcox, R A ; Ristow, K ; Habermann, T M ; Inwards, D J ; Micallef, I N M ; Johnston, P B ; Colgan, J P ; Nowakowski, G S ; Ansell, S M ; Witzig, T E ; Markovic, S N ; Porrata, L</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c542t-8542eceb741e67022c4b7998b8602bfc5bfefb4682d7fa5495710e9d33f46ec83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>692/53/2422</topic><topic>692/699/67/1990/291/1621/1915</topic><topic>Adaptive immunity</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>B-cell lymphoma</topic><topic>Biological and medical sciences</topic><topic>Cancer Research</topic><topic>Continuity (mathematics)</topic><topic>Critical Care Medicine</topic><topic>Development and progression</topic><topic>Female</topic><topic>Hematologic and hematopoietic diseases</topic><topic>Hematology</topic><topic>Humans</topic><topic>Intensive</topic><topic>Internal Medicine</topic><topic>Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis</topic><topic>Lymphocytes</topic><topic>Lymphocytes - pathology</topic><topic>Lymphocytes B</topic><topic>Lymphoma</topic><topic>Lymphoma, Large B-Cell, Diffuse - diagnosis</topic><topic>Lymphoma, Large B-Cell, Diffuse - drug therapy</topic><topic>Lymphoma, Large B-Cell, Diffuse - mortality</topic><topic>Male</topic><topic>Medical prognosis</topic><topic>Medical sciences</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>Monocytes</topic><topic>Monocytes - pathology</topic><topic>Multivariate analysis</topic><topic>Neoplasm Staging</topic><topic>Non-Hodgkin's lymphoma</topic><topic>Non-Hodgkin's lymphomas</topic><topic>Oncology</topic><topic>original-article</topic><topic>Physiological aspects</topic><topic>Prognosis</topic><topic>Retrospective Studies</topic><topic>Risk Factors</topic><topic>Risk groups</topic><topic>Survival</topic><topic>Survival Rate</topic><topic>Tumor microenvironment</topic><topic>Tumors</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wilcox, R A</creatorcontrib><creatorcontrib>Ristow, K</creatorcontrib><creatorcontrib>Habermann, T M</creatorcontrib><creatorcontrib>Inwards, D J</creatorcontrib><creatorcontrib>Micallef, I N M</creatorcontrib><creatorcontrib>Johnston, P B</creatorcontrib><creatorcontrib>Colgan, J P</creatorcontrib><creatorcontrib>Nowakowski, G S</creatorcontrib><creatorcontrib>Ansell, S M</creatorcontrib><creatorcontrib>Witzig, T E</creatorcontrib><creatorcontrib>Markovic, S N</creatorcontrib><creatorcontrib>Porrata, L</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Nursing & Allied Health Database</collection><collection>Immunology Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Nucleic Acids Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection (ProQuest)</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest Central (New)</collection><collection>ProQuest One Academic (New)</collection><collection>ProQuest Health & Medical Research Collection</collection><collection>ProQuest One Academic Middle East (New)</collection><collection>ProQuest One Health & Nursing</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Applied & Life Sciences</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Leukemia</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wilcox, R A</au><au>Ristow, K</au><au>Habermann, T M</au><au>Inwards, D J</au><au>Micallef, I N M</au><au>Johnston, P B</au><au>Colgan, J P</au><au>Nowakowski, G S</au><au>Ansell, S M</au><au>Witzig, T E</au><au>Markovic, S N</au><au>Porrata, L</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The absolute monocyte and lymphocyte prognostic score predicts survival and identifies high-risk patients in diffuse large-B-cell lymphoma</atitle><jtitle>Leukemia</jtitle><stitle>Leukemia</stitle><addtitle>Leukemia</addtitle><date>2011-09-01</date><risdate>2011</risdate><volume>25</volume><issue>9</issue><spage>1502</spage><epage>1509</epage><pages>1502-1509</pages><issn>0887-6924</issn><eissn>1476-5551</eissn><coden>LEUKED</coden><abstract>Despite the use of modern immunochemotherapy regimens, almost 50% of patients with diffuse large-B-cell lymphoma will relapse. Current prognostic models, including the International Prognostic Index, incorporate patient and tumor characteristics. In contrast, recent observations show that variables related to host adaptive immunity and the tumor microenvironment are significant prognostic variables in non-Hodgkin lymphoma. Therefore, we retrospectively examined the absolute monocyte and lymphocyte counts as prognostic variables in a cohort of 366 diffuse large-B-cell lymphoma patients who were treated between 1993 and 2007 and followed at a single institution. The absolute monocyte and lymphocyte counts in univariate analysis predicted progression-free and overall survival when analyzed as continuous and dichotomized variables. On multivariate analysis performed with factors included in the IPI, the absolute monocyte and lymphocyte counts remained independent predictors of progression-free and overall survival. Therefore, the absolute monocyte and lymphocyte counts were combined to generate a prognostic score that identified patients with an especially poor overall survival. This prognostic score was independent of the IPI and added to its ability to identify high-risk patients.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>21606957</pmid><doi>10.1038/leu.2011.112</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0887-6924 |
| ispartof | Leukemia, 2011-09, Vol.25 (9), p.1502-1509 |
| issn | 0887-6924 1476-5551 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_968174121 |
| source | MEDLINE; Springer Nature - Complete Springer Journals; Nature; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals |
| subjects | 692/53/2422 692/699/67/1990/291/1621/1915 Adaptive immunity Adult Aged Aged, 80 and over Antineoplastic Combined Chemotherapy Protocols - therapeutic use B-cell lymphoma Biological and medical sciences Cancer Research Continuity (mathematics) Critical Care Medicine Development and progression Female Hematologic and hematopoietic diseases Hematology Humans Intensive Internal Medicine Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis Lymphocytes Lymphocytes - pathology Lymphocytes B Lymphoma Lymphoma, Large B-Cell, Diffuse - diagnosis Lymphoma, Large B-Cell, Diffuse - drug therapy Lymphoma, Large B-Cell, Diffuse - mortality Male Medical prognosis Medical sciences Medicine Medicine & Public Health Middle Aged Monocytes Monocytes - pathology Multivariate analysis Neoplasm Staging Non-Hodgkin's lymphoma Non-Hodgkin's lymphomas Oncology original-article Physiological aspects Prognosis Retrospective Studies Risk Factors Risk groups Survival Survival Rate Tumor microenvironment Tumors Young Adult |
| title | The absolute monocyte and lymphocyte prognostic score predicts survival and identifies high-risk patients in diffuse large-B-cell lymphoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-21T18%3A22%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20absolute%20monocyte%20and%20lymphocyte%20prognostic%20score%20predicts%20survival%20and%20identifies%20high-risk%20patients%20in%20diffuse%20large-B-cell%20lymphoma&rft.jtitle=Leukemia&rft.au=Wilcox,%20R%20A&rft.date=2011-09-01&rft.volume=25&rft.issue=9&rft.spage=1502&rft.epage=1509&rft.pages=1502-1509&rft.issn=0887-6924&rft.eissn=1476-5551&rft.coden=LEUKED&rft_id=info:doi/10.1038/leu.2011.112&rft_dat=%3Cgale_proqu%3EA268310575%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2645729648&rft_id=info:pmid/21606957&rft_galeid=A268310575&rfr_iscdi=true |